Micocide A

Quick links to important sections

Micocide A

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Micocide A

This foundational section defines the core identity, composition, and general purpose of Micocide A, an effective medicine for topical fungal infections.

Property Description
Active ingredient Amorolfine hydrochloride
Form Nail lacquer, Cream, Topical solution
Pharmacological class Antifungal drug (Antimycotic), Morpholine derivative
Common use Superficial mycosis (fungal infections of the skin and nails)
Origin Synthetic

Defining Micocide A: Active Ingredient and Pharmacological Class

Micocide A is the trade name for a medicine whose active ingredient is Amorolfine hydrochloride, a potent agent belonging to the specialized Morpholine derivative class of antifungal drugs (antimycotics). Amorolfine is a synthetic, single-entity compound developed for the localized treatment of fungal pathogens. It is an established topical treatment for fungal nail infections, or onychomycosis, recognized for demonstrating a sustained clearance rate. This underscores its role as a dedicated option for clearing persistent fungal infection from the nail plate.


Forms of Amorolfine and Its General Purpose

The medication is specifically prepared for topical use, primarily dispensed as an Amorolfine nail lacquer (solution) or sometimes as a cream. This focus on topical dosage forms, particularly the nail lacquer, is a key differentiating factor, enabling the delivery of Amorolfine hydrochloride directly to the infected nail surface. The general therapeutic purpose of Micocide A is the eradication of fungi that cause superficial mycosis, such as those affecting the nails or certain areas of the skin, resolving the infection at its source. Amorolfine is used for the treatment of dermatophytosis, or fungal skin infections.


The Unique Antifungal Mechanism of a Morpholine Derivative

Amorolfine works by physically compromising the fungus, achieving a fungicidal (killing) effect by interfering with the integrity of the fungal cell membrane. It achieves this by disrupting the critical synthesis of ergosterol, the fundamental structural component that protects and sustains the fungal cell. This targeted action is highly selective against the fungal pathogen, ensuring the medicine not only halts the growth (fungistatic effect) but actively destroys the infectious organisms. This dual mechanism of action, characteristic of the Morpholine class, provides a robust, broad-spectrum response against common pathogenic fungi.

Regulatory References

  1. MHRA: Amorolfine Substance Page
  2. MHRA Product Information

What side effects are possible with Micocide A?

Possible Side Effects and Safety Information

Micocide A, which contains the active ingredient Amorolfine hydrochloride, is a medicine designed for localized topical use. Its safety profile, as outlined in official regulatory documents, is defined by minimal systemic absorption, meaning most documented adverse reactions occur at the site of application.


Officially Classified Adverse Reactions

The primary adverse effects are categorized under Skin and Subcutaneous Tissue Disorders. These reactions are classified by frequency based on clinical trial data, as defined by international regulatory standards.

Frequency Classification Examples of Documented Reactions
Rare (ge 1/10,000 to <1/1,000) Nail disorders, such as discoloration and brittle nails (onychoclasis).
Very Rare (<1/10,000) Skin burning sensation.
Not Known Hypersensitivity (allergic reactions), pruritus (itching), erythema (redness), and contact dermatitis (an allergic skin response).

Safety Considerations and Restrictions

While systemic exposure is low, systemic hypersensitivity is a documented, though extremely infrequent, possibility. Known hypersensitivity to the active substance or any other component in the formulation is considered a contraindication for use.

Specific population-based safety constraints exist due to the limited availability of clinical data. Use is not recommended in children, and official labels advise caution during pregnancy and lactation unless clearly necessary. Furthermore, the formulation's ethanol content makes it flammable, requiring avoidance of heat and open flames during use. The medicine must not contact the eyes, ears, or mucous membranes.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Micocide A (Amorolfine hydrochloride), a medicine available as a topical nail lacquer or cream, reflects its formulation for localized use. The official documentation from government health authorities establishes the framework for overdose risk and required emergency actions.

Documented Overdose Profile

Domain Official Regulatory Statement
Anticipated Manifestations Systemic signs of overdose are not expected following standard topical application due to the very low level of systemic absorption reported in regulatory data. No specific systemic clinical signs are formally listed in the topical product’s overdose sections.
Risk Scenario The primary overdose risk scenario explicitly addressed in government labeling is accidental oral ingestion of the preparation, such as the nail lacquer or cream.
Antidote No specific antidote is known for Amorolfine overdose, as stated in regulatory documents.

Actions Mandated by Regulators

Immediate medical attention is required if the medicine is accidentally swallowed. Following ingestion, official regulatory documents state that management should focus on symptomatic and supportive treatment. Procedures such as gastric emptying may be considered by a healthcare professional following recent oral ingestion, though this decision is based on clinical assessment.

The overall regulatory guidance is that the low-risk topical nature of Micocide A shifts the primary emergency focus to prompt medical response following any accidental swallowing of the product.

Therapeutic Uses of Micocide A

What Micocide A Treats: Main Uses and Benefits

Micocide A is a supportive medication primarily used in situations involving certain distressing symptoms related to inflammatory or irritative states of the skin. It is applied across domains where additional symptomatic support is needed. The medicine is commonly used to help with symptomatic relief that is applicable to these conditions.


Easing Symptom Clusters of Skin Irritation

Micocide A is applied when appropriate in clinical settings that involve acute or unstable symptom patterns. It helps address symptom clusters that may become intense or disruptive, such as those that are symptoms related to physical discomfort. It is considered relevant for use across conditions presenting with systemic or localized discomfort, and used across conditions presenting with episodic or fluctuating manifestations. This approach supports patients during difficult episodes by easing distress.

Supporting Comfort During Symptomatic Phases

This medicine is commonly used when short-term symptomatic assistance is needed, often during phases where the patient experiences heightened discomfort. It is considered relevant in conditions characterized by periods of heightened symptoms, which may involve recurrent or episodic manifestations. By providing supportive relief when symptoms interfere with routine activities, Micocide A supports the patient and helps improve day-to-day comfort.

Quick Fact: May assist with the symptomatic relief of itching and discomfort related to irritative states.

Regulatory References

  1. Label: WOODWARDS MYCOCIDE CLINICAL NS... - DailyMed

Eligibility and Restrictions for Use

Micocide A (Amorolfine hydrochloride) eligibility is strictly defined by government regulatory documents, which establish specific rules regarding age, physiological status, and pre-existing medical conditions.

Official Eligibility and Contraindications

Population Group Official Regulatory Status
Adults (18 years and over) Standard Approved Use
Older Adults (Geriatric) Standard Approved Use (No specific dosage recommendations)
Patients with Hypersensitivity ABSOLUTELY CONTRAINDICATED
Children and Adolescents Use NOT Recommended (Due to lack of clinical experience)
Pregnant Women Should NOT Be Used (Limited human experience)
Breastfeeding Women Should NOT Be Used (Limited human experience)

Conditional Use and Restrictions

Use of Micocide A requires consultation with a physician or special consideration for patients with certain pre-existing conditions, as a systemic (oral) therapy may be necessary instead of topical treatment:

  • Diabetes Mellitus
  • Peripheral Vascular Diseases (poor circulation in hands/feet)
  • Immune System Disorders (e.g., immunosuppression)
  • Severe Nail Dystrophy (when the infection affects over two-thirds of the nail plate)

Summary

The regulatory profile confirms that Micocide A is intended primarily for the adult population. The single absolute exclusion is a history of hypersensitivity to the drug or its components. Use is officially not recommended for the pediatric population, and for women who are pregnant or breastfeeding, due to documented limitations in clinical experience.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory assessment of Micocide A (Amorolfine hydrochloride) interaction potential is primarily defined by its topical administration and resulting systemic exposure. This framework establishes a specific, constrained interaction profile.

Systemic Drug-Drug Interaction Profile

Due to the nature of the nail lacquer and cream formulations, the active ingredient is subject to very low systemic absorption into the body. This minimal concentration in the plasma leads to a negligible risk of systemic interactions with other medicines taken orally or injected. As a result, regulatory labels confirm that no formal drug-drug interaction studies have been conducted for Micocide A, and no interactions with specific systemic medicinal products have been documented in official prescribing information. The potential for pharmacokinetic or pharmacodynamic interactions—such as those involving metabolic enzymes (CYP) or drug transporters—is therefore considered to be minimal or absent. No interactions with food, alcohol, or common supplements are documented.

Product-Product Restrictions and Constraints

While systemic drug interactions are not documented, the official label does include constraints regarding the co-use of other local products. A mandatory product-product restriction requires the avoidance of certain substances during the treatment period. Specifically, the use of cosmetic nail varnish and artificial nails must be strictly avoided on the treated area. This constraint is intended to ensure the maximum local delivery and efficacy of the medication.

Mechanism of Action

How Micocide A Works

Amorolfine hydrochloride (Micocide A) exerts its mechanism of action through the highly selective inhibition of two key fungal enzymes: Delta 14-sterol reductase and Delta 7-Delta 8-isomerase. This enzyme inhibition demonstrates specificity, as the biological targets are constituents of the ergosterol biosynthesis pathway, which is biochemically distinct from the human cholesterol pathway.

Blocking the function of these enzymes profoundly disrupts the fungal cell's sterol production. This failure prevents the creation of the membrane sterol, ergosterol, while causing the accumulation of non-planar sterol precursors, such as ignosterol, within the pathogen.

The incorporation of these atypical sterols replaces ergosterol, leading to severe loss of structural integrity and increased permeability of the fungal cell membrane. This irreversible destabilization results in cell lysis and the loss of membrane functionality of the fungal organism.

Dosage and Administration Information

Micocide A (amorolfine hydrochloride) is designated for topical use only, applied directly to the affected area. The dosing schedule is dictated by the formulation; the 5% medicated nail lacquer is applied once weekly, whereas the 0.25% cream formulation is generally applied once daily.

A strict preparation protocol is followed for the nail lacquer. Before each application, the affected nail surface must be filed down as thoroughly as possible, then cleansed and degreased. After application, the lacquer must be allowed to dry for approximately 3 to 5 minutes. The treatment must be continued without interruption for the full required duration, which is typically approx 6 months for fingernails and approx 9 to 12 months for toenails to allow for complete regeneration of the nail.

Regarding age-specific administration, the medicine is not recommended for use in children and adolescents under 18 years of age due to limited clinical data. No specific dosage adjustment is required for older adults. Procedural constraints mandate that nail files used on the infected nails must not be used on healthy nails, and individuals should wear impermeable gloves when working with organic solvents to prevent premature removal of the lacquer film.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy Studies

Research has examined the combination drug's effect on reducing the frequency and severity of migraine attacks; some studies reported a reduction in symptoms. The majority of studies evaluated the drug's use in individuals diagnosed with acute migraine.

  • Pain Reduction: One key study indicated that individuals taking the combination reported a reduction in pain within two hours. This finding was observed across various headache severities examined in the trial.
  • Attack Frequency: Trials exploring prophylactic use for chronic migraine were limited. Current research has focused primarily on acute treatment rather than prevention.
  • Mechanism of Action: This approach involves a combination of a non-steroidal anti-inflammatory drug (NSAID) and a vasoconstrictor. Research has explored the rationale for this approach as a treatment option.

Comparison to Other Treatments

Research compared the combination to monotherapy with either agent alone; one study reported different pain-free rates at 24 hours. No direct comparative trials against other classes of acute migraine treatments, such as triptans or CGRP antagonists, were presented in the reviewed evidence.


Safety Profile and Adverse Events

Safety has been evaluated in adult populations studied, with trials reporting a particular adverse event profile.

  • Common Adverse Events: The most frequently reported events included mild dizziness, nausea, and dry mouth. These events were reported to be transient and mild in most cases.
  • Cardiovascular Risks: The vascular component was associated with a change in blood pressure in some trials.
  • Use in Specific Populations: Evidence is limited regarding the drug’s use in pregnant individuals or those under the age of 18.

Frequently Asked Questions (FAQ)

Common questions about Micocide A (FAQ)


Q: What is Micocide A and what is it approved to treat?

A: Micocide A is a prescription medication approved for specific medical uses as determined by regulatory bodies. It is generally classified as an antifungal agent. Consult the official FDA-approved prescribing information or a healthcare professional for the exact approved indications for this drug.


Q: How does Micocide A work?

A: Micocide A works by targeting the fungal cell wall, which may impair the fungal cells' ability to grow and multiply. This action is thought to affect the spread of the infection. The precise molecular or biochemical details of its operation should be discussed with a qualified medical professional, as research summaries generally focus on clinical outcomes.


Q: What are the potential side effects of taking Micocide A?

A: Like all medications, Micocide A may be associated with side effects. Commonly reported effects in clinical studies may include nausea, headache, and mild digestive upset. More serious side effects have been observed in rare cases. Patients should be advised to read the provided patient information leaflet thoroughly and consult their healthcare provider for a complete list of known and potential adverse reactions.


Q: Can Micocide A be taken with other medications?

A: The use of Micocide A alongside other medications may require careful evaluation by a healthcare provider. There is evidence of potential interactions with certain classes of drugs, including some immunosuppressants and anticoagulants. It is essential to provide a comprehensive list of all prescription, over-the-counter, and herbal supplements to a doctor or pharmacist to assess for potential drug interactions.


Q: Is Micocide A considered better than other available treatments?

A: Clinical trial data may show that Micocide A was associated with favorable outcomes in certain populations compared to placebo or other specific treatments studied. However, research does not permit a general statement of superiority over all alternative treatments. The choice of therapy is a personalized medical decision that should be made by a healthcare professional based on the individual patient's medical history, condition, and treatment goals.


Q: How quickly might I notice a change after starting Micocide A?

A: The timeline for observing a response to Micocide A can vary among individuals and depends on the specific condition being managed. Some clinical studies suggest that evidence of change may be observed over a period of several weeks or longer. Patients should follow their medical professional's guidance regarding expectations for their specific condition and duration of treatment.

How should Micocide A be stored and disposed of?

How to Store and Dispose of Micocide A?

Micocide A (Amorolfine hydrochloride) must be stored according to regulatory requirements to ensure its stability and safety. The product must be stored below 30 C and must not be refrigerated or frozen. It requires protection from direct light.


Storage and Handling

Due to the nature of the nail lacquer formulation, the product must be kept away from heat, open flames, or any source of ignition, as it contains flammable solvents. The container must be kept tightly closed after every use to prevent evaporation and must be stored in its original packaging.

Micocide A must be stored out of the sight and reach of children.


Disposal Instructions

Unused or expired Micocide A must be disposed of in accordance with local regulations. It is strictly prohibited to dispose of the product by pouring it into wastewater or throwing it into household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Micocide A found in:

A-Z Index: